Hormone, or endocrine, therapy forms a foundational component of breast cancer care for patients whose tumours test positive for hormone receptors. In Canada, common treatments such as tamoxifen and aromatase inhibitors act to impair cancer cell growth by blocking the effects of estrogen or reducing hormone production. These therapies are typically used in early-stage breast cancers and may be continued for several years following primary treatment to reduce the likelihood of recurrence.

Provincial guidelines established by organizations like Cancer Care Ontario and BC Cancer set out eligibility and duration recommendations, reflecting the evolving evidence base. Patient decisions regarding hormone therapy are often discussed in multidisciplinary teams, considering potential side effects such as bone density loss, cardiovascular risk, and menopausal symptoms, balanced against treatment benefits. Canadian hospitals routinely offer support for managing hormone therapy–related side effects.
Medications for endocrine therapy are usually dispensed in oral tablet form, making home-based use possible. Many provinces provide public insurance coverage for these drugs, either fully or partially, for qualifying residents. Private insurance and copayment mechanisms can influence individual access and out-of-pocket costs, with Canadian patients encouraged to consult regional cancer support programs for updated information on financial assistance and drug reimbursement.
Hormone therapies are subject to ongoing research in Canada, including studies of extended-duration treatments, alternate dosing, and novel combination regimens. Collaboration among Canadian research networks helps to gather real-world data and adapt clinical protocols. Performance monitoring by cancer registries ensures national and provincial programs can identify emerging patterns and potential areas for further refinement in patient care.